2-Amino-N-(amino-oxo-aryl-lambda 6-sulfanylidene)acetamide compounds and their therapeutic uses

2-amino-N-(amino-oxo-aryl-λ6-sulfanylidene)acetamide compounds selectively target bacterial leucyl-tRNA synthetases, addressing resistance issues and providing an effective treatment for bacterial infections.

JP7591056B2Active Publication Date: 2024-11-27OXFORD DRUG DESIGN LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022536992
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-19
Filing Date
2020-12-18
Publication Date
2024-11-27
Estimated Expiration
2040-12-18

AI Technical Summary

Technical Problem

Current antimicrobial agents face challenges with widespread resistance, necessitating new chemotherapeutic agents that target bacterial aminoacyl-tRNA synthetases to inhibit bacterial infections effectively.

Method used

Development of 2-amino-N-(amino-oxo-aryl-λ6-sulfanylidene)acetamide compounds (ANASIA compounds) that selectively inhibit bacterial leucyl-tRNA synthetases, offering a novel approach to treat bacterial infections.

Benefits of technology

The ANASIA compounds provide a potent mechanism to inhibit bacterial aminoacyl-tRNA synthetases, potentially overcoming resistance issues and effectively treating a wide range of bacterial infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591056000001
    Figure 0007591056000001
  • Figure 0007591056000002
    Figure 0007591056000002
  • Figure 0007591056000003
    Figure 0007591056000003
Patent Text Reader

Abstract

The present invention relates generally to the field of therapeutic compounds. More particularly, the present invention relates to the preparation of certain 2-amino-N-(amino-oxo-aryl-λ) tRNA synthetases that inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetases (aaRS) (e.g., bacterial leucyl-tRNA synthetases, LeuRS). 6 The present invention relates to (e.g., selectively inhibiting) bacterial aminoacyl-tRNA synthetases, treating disorders ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetases, treating bacterial infections, and other uses of such compounds and compositions, both in vitro and in vivo. [Formula 1] TIFF2023506894000322.tif18141
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Novel n-acyl-arylsulfonamide derivatives as aminoacyl trna synthetase inhibitors

    JP2018507257A

  • 2-amino-n-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-TRNA synthetase

    WO2018065611A1